| Literature DB >> 33081337 |
Roberta Zupo1, Fabio Castellana1, Francesco Panza1,2, Luisa Lampignano1, Isanna Murro3, Carmen Di Noia3, Vincenzo Triggiani4, Gianluigi Giannelli5, Rodolfo Sardone1, Giovanni De Pergola1,3.
Abstract
Much research suggests that Mediterranean eating habits and lifestyle contribute to counteract the risk of chronic diseases while promoting longevity, but little information is available on the effects of the Mediterranean diet (Med-Diet) on thyroid function, particularly among overweight/obese subjects. Nevertheless, consistent data reported a slight increase in serum levels of the thyroid-stimulating hormone (TSH) and a higher rate of conversion of thyroxine (T4) to triiodothyronine (T3) in obesity. This cross-sectional study was aimed at investigating the relationship between adherence to the Med-Diet and circulating thyroid hormones in a cohort of overweight/obese subjects from Apulia (Southern Italy).Entities:
Keywords: Italy; mediterranean diet; obesity; thyroid hormones
Mesh:
Substances:
Year: 2020 PMID: 33081337 PMCID: PMC7603040 DOI: 10.3390/nu12103173
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Description of the whole sample divided by adherence to Mediterranean diet (Med-Diet) (N = 324).
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Proportions | 59 (18.20) | -- | 265 (81.80) | -- | |
| Age (years) | 38.034 ± 13.165 | 37 (19 to 72) | 42.494 ± 13.157 | 45 (14 to 71) |
|
|
| |||||
|
| 23 (24.00) | -- | 73 (76.00) | -- | 0.08 χ2 |
|
| 36 (15.80) | -- | 192 (72.50) | -- | |
| BMI (Kg/m2) | 34.334 ± 5.579 | 33.5 (26.1 to 47.3) | 32.914 ± 5.374 | 31.5 (24 to 49.3) | 0.073 |
| Waist Circumference (cm) | 111.661 ± 15.952 | 114 (81 to 150) | 107.536 ± 12.582 | 106 (79 to 147) | 0.067 |
| SBP (mmHg) | 129.186 ± 18.1 | 130 (86 to 180) | 128.649 ± 16.122 | 130 (90 to 172) | 0.686 |
| DBP (mmHg) | 85.237 ± 12.934 | 85 (55 to 116) | 83.532 ± 11.409 | 84 (56 to 120) | 0.277 |
| FBG (mg/dL) | 88.776 ± 10.122 | 87.5 (70 to 118) | 89.782 ± 12.884 | 88 (65 to 143) | 0.744 |
| Insulin (μUI/mL) | 14.991 ± 9.367 | 12 (4.3 to 46) | 14.201 ± 9.55 | 11.5 (2.4 to 67) | 0.471 |
| HOMA index | 3.348 ± 2.262 | 2.77 (0.74 to 11.1) | 3.189 ± 2.266 | 2.51 (0.52 to 14.5) | 0.479 |
| HbA1c (%) | 5.359 ± 0.423 | 5.375 (4.6 to 6.9) | 5.374 ± 0.485 | 5.35 (4 to 8.9) | 0.982 |
| Total cholesterol (mg/dL) | 190.702 ± 39.88 | 190 (125 to 298) | 194.695 ± 38.747 | 192 (51 to 310) | 0.467 |
| HDL cholesterol (mg/dL) | 48.526 ± 14.345 | 44 (24 to 89) | 52.092 ± 13.395 | 50 (27 to 116) | 0.022 |
| LDL cholesterol (mg/dL) | 123.982 ± 35.071 | 122 (69 to 262) | 122.494 ± 33.396 | 118 (32 to 221) | 0.899 |
| Triglycerides (mg/dL) | 109.797 ± 60.549 | 101 (39 to 400) | 105.781 ± 62.04 | 93 (31 to 541) | 0.451 |
| TSH (microUI/mL) | 1.786 ± 0.993 | 1.6 (0.38 to 4.31) | 1.927 ± 1.055 | 1.67 (0.29 to 6.37) | 0.321 |
| FT3 (pg/mL) | 3.122 ± 0.397 | 3.105 (2.1 to 3.9) | 2.993 ± 0.415 | 2.995 (1.64 to 4.6) |
|
| FT4 (pg/mL) | 10.911 ± 1.508 | 10.75 (8 to 16.5) | 10.23 ± 1.341 | 10.1 (6.8 to 14.5) |
|
| PTH (pg/mL) | 32.367 ± 17.081 | 28.25 (5.2 to 98.6) | 31.32 ± 12.893 | 29 (7.46 to 76.7) | 0.928 |
| Uric acid (mg/dL) | 5.098 ± 1.651 | 4.9 (2.1 to 10.4) | 4.603 ± 1.393 | 4.5 (2.1 to 9.4) |
|
| Creatinine (mL/min) | 0.766 ± 0.15 | 0.755 (0.48 to 1.16) | 0.768 ± 0.161 | 0.75 (0.46 to 1.26) | 0.852 |
* Wilcoxon sum rank test, ꭓ2 Chi squared test. Data are shown as mean ± SD (Standard Deviation), median and range for continuous variables and as (%) for proportions. Significance shown in bold. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: Fasting Blood Glucose; HOMA: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Hemoglobin A1c; HDL cholesterol: high-density lipoprotein cholesterol; LDL cholesterol: low-density lipoprotein cholesterol; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine; FT4: free thyroxine; PTH: Parathyroid Hormone.
Multinomial logistic regression models on FT4 and FT3 tertiles as dependent variables.
| FT4 Tertiles | FT3 Tertiles | ||||||
|---|---|---|---|---|---|---|---|
| Raw Models | |||||||
| OR | CI 95% | OR | CI 95% | ||||
| PREDIMED score (>7) | 2nd tertile |
|
|
| 0.75 | 0.35 to 1.60 | 0.46 |
| 3rd tertile |
|
|
| 0.46 | 0.22 to 0.94 |
| |
| Semi-adjusted models * | |||||||
| 2nd tertile |
|
|
| 0.87 | 0.40 to 1.89 | 0.72 | |
| 3rd tertile |
|
|
| 0.53 | 0.25 to 1.12 | 0.09 | |
| Fully-adjusted models ** | |||||||
| 2nd tertile |
|
|
| 1.10 | 0.41 to 2.89 | 0.84 | |
| 3rd tertile |
|
|
| 0.61 | 0.24 to 1.57 | 0.31 | |
Significance shown in bold. * corrected for age, gender, SBP (Systolic Blood Pressure), DBP (Diastolic Blood Pressure), and BMI (Body Mass Index). ** corrected for semi-adjusted plus olive oil consumption (>4 servings/day) and vegetables consumption (>2 servings/day). Abbreviations: FT3 (free triiodothyronine); FT4 (free thyroxine). OR: Odds Ratio; CI: Confidence Interval; PREDIMED: (PREvención con DIeta MEDiterránea).
Distribution across thyroid hormones tertiles according to the PREDIMED (PREvención con DIeta MEDiterránea) score.
| PREDIMED Score <7 | PREDIMED Score ≥7 | |||
|---|---|---|---|---|
| TSH | Q1 (0.29–1.28) | 20 (34.50) | 86 (33.30) | 0.86 |
| Q2 (1.29–2.16) | 20 (34.50) | 85 (32.90) | 0.82 | |
| Q3 (2.17–6.37) | 18 (31.00) | 87 (33.70) | 0.69 | |
| FT3 | Q1 (1.64–2.83) | 14 (24.10) | 90 (35.40) | 0.09 |
| Q2 (2.84–3.17) | 18 (31.00) | 87 (34.30) | 0.63 | |
| Q3 (3.18–4.60) | 26 (44.80) | 77 (30.30) |
| |
| FT4 | Q1 (6.80–9.72) | 9 (15.50) | 95 (37.40) |
|
| Q2 (9.73–10.80) | 23 (39.70) | 85 (33.50) | 0.37 | |
| Q3 (10.81–16.50) | 26 (44.80) | 74 (29.10) |
|
Data shown as count and (%). * Chi-squared test. Abbreviations: TSH (thyroid-stimulating hormone); FT3 (free triiodothyronine); FT4 (free thyroxine).